Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) in patients with unresectable biliary tract cancer treated with gemcitabine, cisplatin, and durvalumab

Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) in patients with unresectable biliary tract cancer treated with gemcitabine, cisplatin, and durvalumab

Abstract Background Biliary tract cancer (BTC) is a type of malignancy that is challenging to manage. Further, advanced-stage BTC has poor prognosis. Based on the recent TOPAZ-1 trial, adding durvalumab to gemcitabine and cisplatin significantly improves survival in unresectable BTC, thereby making...

Full description

Saved in:
Bibliographic Details
Main Authors: Satoshi Mii, Hiroyuki Kato, Takeshi Takahara, Masayuki Kojima, Yutaro Kato, Zenichi Morise, Akihiko Horiguchi, Koichi Suda
Format: Article
Language:English
Published: BMC 2025-07-01
Series:World Journal of Surgical Oncology
Subjects:
Biliary tract cancer
Durvalumab
Neutrophil-to-lymphocyte ratio
Online Access:https://doi.org/10.1186/s12957-025-03834-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items